| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Mar | May » | |||||
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 | ||||||
April 2nd, 2012 tmccoy
by: Stephanie Herschaft, Esq. Young adults today have a significantly higher risk of melanoma, the most dangerous form of skin cancer, than they did four decades ago. Researchers at the Mayo Clinic found that the risk of young women developing melanoma is six times higher than it was just forty years ago. The risk for [...]
April 2nd, 2012 tmccoy
by: Matthew McCauley, Esq. In a study published today in the Canadian Medical Association Journal, results indicated that women taking Bisphosphonates (FOSAMAX/BONIVA/ACTONE) for the first time had a 45 percent increased risk of eye disorders uvelitis and scleritis within 30 to 90 days from initiation of the product’s use. While researchers believe that the disorders [...]
April 2nd, 2012 tmccoy
by: Michael Werner, Esq. On March 29, 2012, a Food and Drug Administration (“FDA”) advisory committee voted 17 to 6 in favor of imposing mandatory clinical trials on future obesity drugs. The clinical trial requirement will apply to all future drugs within that class and will serve to ensure that the drugs do not pose [...]
